Wird geladen...
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
Venetoclax (VEN), a small-molecule inhibitor of B cell leukemia/lymphoma-2, is now FDA approved (November 2018) for use in acute myeloid leukemia (AML), specific to newly diagnosed elderly or unfit patients, in combination with a hypomethylating agent (HMA; including azacitidine or decitabine) or lo...
Gespeichert in:
| Veröffentlicht in: | Blood Cancer J |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Nature Publishing Group UK
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7684277/ https://ncbi.nlm.nih.gov/pubmed/33230098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00388-x |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|